A systematic review 1 including 5 RCTs with a total of 156 subjects and 10 uncontrolled studies (not included in the meta-analysis) was abstracted in DARE. The rate of response or remission was 18.4% in the treatment group and 1.5% in the control group. The best two results for long-term remission were 3.3% for lymphoblastoid IFN-alpha, and 8% for IFN-alpha 2b.
Comment: The quality of evidence is downgraded by sparse data.
Primary/Secondary Keywords